Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

BACKGROUND: Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913298/
https://www.ncbi.nlm.nih.gov/pubmed/35427842
http://dx.doi.org/10.1016/j.esmoop.2022.100458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913298/
https://www.ncbi.nlm.nih.gov/pubmed/35427842
http://dx.doi.org/10.1016/j.esmoop.2022.100458

Ejemplares similares